KR101869406B1 - Controlled Released Hard Capsule Preparation - Google Patents
Controlled Released Hard Capsule Preparation Download PDFInfo
- Publication number
- KR101869406B1 KR101869406B1 KR1020150165457A KR20150165457A KR101869406B1 KR 101869406 B1 KR101869406 B1 KR 101869406B1 KR 1020150165457 A KR1020150165457 A KR 1020150165457A KR 20150165457 A KR20150165457 A KR 20150165457A KR 101869406 B1 KR101869406 B1 KR 101869406B1
- Authority
- KR
- South Korea
- Prior art keywords
- release
- drug
- hard capsule
- polymer
- layer
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Abstract
[0001] The present invention relates to a controlled-release hard capsule preparation, and more particularly, to a capsule containing a first drug or a pharmaceutically acceptable salt thereof and a fast acting excipient; And a sustained release comprising a second drug or a pharmaceutically acceptable salt thereof and a release controlling polymer.
Description
[0001] The present invention relates to a controlled-release hard capsule preparation, and more particularly, to a capsule containing a first drug or a pharmaceutically acceptable salt thereof and a fast acting excipient; And a sustained release comprising a second drug or a pharmaceutically acceptable salt thereof and a release controlling polymer.
In the pharmaceutical industry, the drug delivery system technology that effectively transfers the necessary amount of drug to the action site in order to maximize the efficacy and the effect while minimizing the adverse effect of the drug along with the development of the new drug has been dramatically developed in order to create added value. In particular, the Controlled Released Drug Delivery System (DDS) technology, which slowly releases the drug and reduces the number of doses, is making rapid progress with this need. Drugs that are administered more than once a day may be converted to once-a-day dosing by this controlled-release drug delivery system technique to improve the patient's compliance with the medication. If the maximum blood concentration is above the effective blood level or the sudden drug Can increase the efficacy of the drug by increasing the effective blood concentration retention time.
However, despite the breakthrough of release-controlled drug delivery system technology, the application of conventional release-controlled drug delivery system techniques can achieve sustained release of the drug, There is a case that can not be done. Particularly, in the case of a drug which is poorly soluble and is administered into the body and the absorption is restricted to the small intestine, the bioavailability of the drug is markedly lowered when the drug is orally administered.
In view of the fact that it is difficult to maintain a rapid and constant pharmacological effect in a sustained-release pattern of a general drug, a two-phase elution is performed so as to allow release from the absorption site while exhibiting rapid drug efficacy after administration It is desirable to design formulations that not only have a profile (immediate release phase and delayed release phase) but also exhibit extended stagnation properties.
On the other hand, the development of a combination preparation having two or more pharmacological ingredients as one formulations to increase the convenience of taking and to reduce the content of each ingredient through synergistic action, thereby minimizing side effects and maximizing the therapeutic effect It is actively being done.
In the case of such a combination preparation, one ingredient may interfere with the absorption, distribution and metabolism of other ingredients during the absorption, metabolism, distribution, efficacy and excretion of the drug to reduce drug efficacy or increase side effects, It is required to develop an agent that can increase the drug efficacy and reduce the side effects, as compared with the case where the two components are separately administered as a single agent.
Thus, the present inventors have found that the present invention can provide a pharmaceutical composition which can exhibit an elongated stagnation property and a two-phase elution profile (immediate release phase and delayed release phase) so that the rapid pharmacological effect can be manifested and the pharmacological effect can be maintained for a long period, The present invention provides a pharmaceutical composition comprising a first drug or a pharmaceutically acceptable salt thereof and a fast acting excipient; And a sustained release comprising a second drug or a pharmacologically acceptable salt thereof and a release controlling polymer, wherein the preparation has a sustained uptake time and an initial effective blood concentration of the drug, And exhibits a specific elution profile capable of maintaining an effective blood concentration, thus completing the present invention. U.S. Patent Application Laid-Open Publication No. US2008 / 0085306 (April 10, 2008). U.S. Patent Application Publication No. 2003/0077297 (Apr. 24, 2003).
It is an object of the present invention to provide a pharmaceutical composition which exhibits an extended stomach retention property and a two-phase elution profile (immediate release phase and delayed release phase) to enable rapid pharmacological effect development and long-term pharmacological effect maintenance, The present invention provides a release-controlled hard capsule preparation which can be eluted with a time difference.
In accordance with the above object,
A fastener comprising a first drug or a pharmaceutically acceptable salt thereof and a fast acting excipient; And
A second drug or a pharmaceutically acceptable salt thereof, and a release-controlling polymer including a release-controlling polymer.
Wherein the first drug is selected from the group consisting of rosacean, propranolol, metoprolol, verapamil, caberdiol, nimodipine, nicardipine, ferrodipine, amlodipine, enalapril, captopril, ramipril, lisinopril, , Tamsulosin, simvastatin, lovastatin, pravastatin, fluvastatin, cimetidine, famotidine, ranitidine, nizatidine, omeprazole, s omeprazole, lansoprazole, pantoprazole, rabeprazole, tenatoprazole, domperidone, But are not limited to, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, Nitrofurantoin, atomocetin, tetracycline, oseltamivir, valacyclovir, diazepam, chlorodiaxanthide, imipramine, methylphenidate , May be selected from the trazodone, venlafaxine, Amit leaf ethylene, bupropion, gabapentin, quetiapine, zolpidem, saponite draw rate, cilostazol, non-carboxylic wave, levodopa and oxybutynin group consisting of.
The fast acting excipient may be selected from the group consisting of lactose, sucrose, dextrin, mannitol, xylitol, sorbitol, starch, microcrystalline cellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, calcium hydrogenphosphate, And mixtures thereof.
Wherein the second drug is selected from the group consisting of rosatan, propranolol, metoprolol, verapamil, caberdiol, nimodipine, nicardipine, ferrodipine, amlodipine, enalapril, captopril, ramipril, lisinopril, , Tamsulosin, simvastatin, lovastatin, pravastatin, fluvastatin, cimetidine, famotidine, ranitidine, nizatidine, omeprazole, s omeprazole, lansoprazole, pantoprazole, rabeprazole, tenatoprazole, domperidone, But are not limited to, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, Nitrofurantoin, atomocetin, tetracycline, oseltamivir, valacyclovir, diazepam, chlorodiaxanthide, imipramine, methylphenidate , May be selected from the trazodone, venlafaxine, Amit leaf ethylene, bupropion, gabapentin, quetiapine, zolpidem, saponite draw rate, cilostazol, non-carboxylic wave, levodopa and oxybutynin group consisting of.
The first drug and the second drug may be the same or different.
In the hard capsule preparation of the present invention wherein the first drug and the second drug are the same, the inner part comprises 20 to 40% by weight of the total weight of the active ingredient drug, and the western part comprises 60 to 80% Lt; / RTI >
The release controlling polymer may be at least one selected from the group consisting of hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carbomer, polyethylene oxide, carnenan, natural gum, guar gum, tragacanth, acacia gum, locust bean gum, xanthan gum, alginate , Polyvinyl alcohol, polyvinyl pyrrolidone, and mixtures thereof. The hydrophilic polymer may be at least one selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, and mixtures thereof.
In the hard capsule preparation of the present invention, the sustained-release part is formed from the group consisting of a methacrylic acid copolymer, ethyl cellulose, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, cellulose acetate phthalate, and mixtures thereof as a release- And may further include a hydrophobic polymer selected from one or more species.
In the hard capsule preparation of the present invention, the extended part may contain 12 to 25% by weight, based on the total weight of the sustained release polymer, of the release-controlled polymer.
The sustained release may further comprise a pharmaceutically acceptable excipient.
The pharmaceutically acceptable excipient for use in the sustained release may be selected from lactose, sucrose, dextrin, mannitol, sorbitol, copovidone, methylcellulose, ethylcellulose, Calcium stearate, calcium stearate, croscarmellose sodium, crospovidone, carboxymethyl starch, methacrylate-divinylbenzene copolymer calcium, microcrystalline cellulose, starch, cyclodextrin, pregelatinized starch, Magnesium stearate, magnesium stearate, calcium stearate, glyceryl monostearate, sodium stearyl fumarate, talc, and mixtures thereof.
The inner zone may be in the form of granules and the middle zone may be in the form of pellets or mini tablets.
The pellet comprises a release coating layer comprising a) an inert core, b) a drug coating layer comprising a second drug formed on the surface of the inert core and a pharmaceutically acceptable excipient, and c) a polymer for release control formed on the surface of the drug coating layer May include.
In the pellet, the release-controlling layer formed on the surface of the drug coating layer may be a single layer or two or more multi-layered layers.
In the pellet, the release controlling layer may include a first release controlling layer formed on the surface of the drug coating layer and containing a mixture of a hydrophilic polymer and a hydrophobic polymer as a release controlling polymer, and a hydrophilic polymer as a release controlling polymer formed on the surface of the first release controlling layer. And the second emission control layer.
In the hard capsule preparation of the present invention, the mini tablet is prepared by mixing a) an inert core, b) a drug coating layer comprising a second drug formed on the surface of the inert core and a pharmaceutically acceptable excipient, and c) The pellet containing the release-controlling layer containing the polymer may be compression molded. The release control layer formed on the mini tablet surface may be a single layer or two or more multi-layered layers. In the mini tablet, the release control layer may include a first release control layer formed on the surface of the drug coating layer and including a mixture of a hydrophilic polymer and a hydrophobic polymer as a release control polymer, and a hydrophilic polymer as a release control polymer formed on the surface of the first release control layer. And the second emission control layer.
In the hard capsule preparation of the present invention, the mini-tablet may be a micro-tablet comprising a second drug and a pharmaceutically acceptable excipient and having a release-controlling layer containing a release-controlling polymer on the surface thereof. Wherein the release control layer comprises a first release control layer comprising a mixture of a hydrophilic polymer and a hydrophobic polymer as a release control polymer formed on the mini tablet surface, and a second release control layer formed on the surface of the first release control layer, the release control layer comprising a hydrophilic polymer 2 emission control layer.
The hard capsule preparation of the present invention may be administered once a day.
The controlled-release hard capsule preparation of the present invention comprises a first drug or a pharmaceutically acceptable salt thereof and a fast acting excipient; And a sustained release comprising a second drug or a pharmaceutically acceptable salt thereof and a release controlling polymer, thereby exhibiting an extended stomach retention and a two-phase elution profile (immediate release phase and delayed release phase) It is possible to exhibit a rapid pharmacological effect and to maintain the pharmacological effect for a long period of time.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a schematic view showing a hard capsule preparation of controlled release type comprising a fast-release granule and a sustained-release pellet as one embodiment of the present invention.
Fig. 2 is a schematic diagram showing a controlled-release hard capsule preparation containing an immediate-preservative granule and a sustained-release mini-tablet as an embodiment of the present invention.
According to the present invention,
A fastener comprising a first drug or a pharmaceutically acceptable salt thereof and a fast acting excipient; And
A second drug or a pharmaceutically acceptable salt thereof, and a release-controlling polymer including a release-controlling polymer.
The hard capsule preparation of the present invention exhibits a two-phase elution profile in which the first phase comprises a first drug or a pharmaceutically acceptable salt thereof and an immediate-release excipient as an immediate release or immediate release phase, And the second phase is controlled by a sustained release containing a second drug or a pharmaceutically acceptable salt thereof and a release-controlling polymer as a delayed-release or sustained-release phase. In addition, since the hard capsule preparation according to the present invention can enhance the gastric adhesiveness of the western part by the release-controlling polymer contained in the western part, the residence time of the drug can be prolonged. Furthermore, it is possible to control the bioavailability by adjusting the content of the release-controlled polymer in the western part and the content of the immediate-release part and the western part to control the elution time and stagnation property. Accordingly, when the first drug and the second drug are the same, the hard capsule preparation of the present invention can be administered once a day by controlling the mechanism of release of the drug by the rapid and slow release phases and the gastric retentivity.
In the hard capsule preparation of the present invention wherein the first drug and the second drug are the same, the inner part comprises 20 to 40% by weight of the total weight of the active ingredient drug, and the western part comprises 60 to 80% .
Meanwhile, the hard capsule preparation of the present invention is capable of separating the dissolution pattern of the immediate-release phase and the sustained-release phase by each of the immediate-release and extended-release forms in one formulation, and thus exhibits different release patterns without affecting the mutual release Controlled release of the formulation is possible. When the first drug and the second drug are made into different combination preparations, time elution is enabled, which is more suitable for increasing the drug efficacy and reducing the side effects than when the two components are separately administered as a single drug.
Wherein the first drug is selected from the group consisting of rosacean, propranolol, metoprolol, verapamil, caberdiol, nimodipine, nicardipine, ferrodipine, amlodipine, enalapril, captopril, ramipril, lisinopril, , Tamsulosin, simvastatin, lovastatin, pravastatin, fluvastatin, cimetidine, famotidine, ranitidine, nizatidine, omeprazole, s omeprazole, lansoprazole, pantoprazole, rabeprazole, tenatoprazole, domperidone, But are not limited to, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, Nitrofurantoin, atomocetin, tetracycline, oseltamivir, valacyclovir, diazepam, chlorodiaxanthide, imipramine, methylphenidate , May be selected from the trazodone, venlafaxine, Amit leaf ethylene, bupropion, gabapentin, quetiapine, zolpidem, saponite draw rate, cilostazol, non-carboxylic wave, levodopa and oxybutynin group consisting of.
Wherein the second drug is selected from the group consisting of rosatan, propranolol, metoprolol, verapamil, caberdiol, nimodipine, nicardipine, ferrodipine, amlodipine, enalapril, captopril, ramipril, lisinopril, , Tamsulosin, simvastatin, lovastatin, pravastatin, fluvastatin, cimetidine, famotidine, ranitidine, nizatidine, omeprazole, s omeprazole, lansoprazole, pantoprazole, rabeprazole, tenatoprazole, domperidone, But are not limited to, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, Nitrofurantoin, atomocetin, tetracycline, oseltamivir, valacyclovir, diazepam, chlorodiaxanthide, imipramine, methylphenidate , May be selected from the trazodone, venlafaxine, Amit leaf ethylene, bupropion, gabapentin, quetiapine, zolpidem, saponite draw rate, cilostazol, non-carboxylic wave, levodopa and oxybutynin group consisting of.
The term " fast acting excipient " as used herein means a substance that rapidly elutes the drug of the immediate release and facilitates granulation. The fast acting excipients that can be used in the present invention include lactose, sucrose, dextrin, mannitol, xylitol, sorbitol, starch, microcrystalline cellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, calcium hydrogen phosphate, But may be selected from the group consisting of hydrogen, calcium, calcium carbonate, and mixtures thereof, but is not limited thereto.
In the present invention, the immediate-release part may contain 30 to 70% by weight of the quick-acting excipient based on the total weight of the immediate-release part. When the quick-acting excipient is used in an amount less than 30% by weight based on the total weight of the sustained-release excipient, the elution of the active ingredient may be delayed and the rapid drug efficacy may be delayed. Which can cause side effects.
As used herein, the term "extended release " means a formulation that slowly dissolves in the body after administration and slowly elutes the drug.
The sustained release of the present invention is characterized by comprising a second drug or a pharmaceutically acceptable salt thereof and a release-controlling polymer.
The term "release controlling polymer " as used in the present invention means a substance that is used to release a drug over a long period of time. The release-controlling polymer may be a hydrophilic polymer that exhibits release control and mucoadhesiveness to improve sustained release and stagnation properties, or a pharmaceutically acceptable hydrophobic polymer that is not dissolved or hardly soluble in water together with such a hydrophilic polymer Can be used.
Examples of the hydrophilic polymer having mucoadhesive properties include hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carbomer, polyethylene oxide, carnenan, natural gum, guar gum, tragacanth, acacia gum, locust bean gum, But is not limited to, at least one selected from the group consisting of gum, alginate, polyvinyl alcohol, polyvinyl pyrrolidone, and mixtures thereof.
In the present invention, the release-controlling polymer is preferably a hydrophilic polymer which exhibits release control and adhesion to the mucous membranes and is capable of improving the release properties and stagnation properties. Specifically, the release-controlling hydrophilic polymer is capable of absorbing body fluids after oral administration to form a matrix to control the release of the drug, as well as allowing the slow outer layer to adhere to the gastric mucosa / So that it can stay on the floor until the adhesive strength is weakened by continuous shearing action.
In the present invention, the hydrophobic polymer which can be used as a polymer for emission control is selected from the group consisting of methacrylic acid copolymer, ethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate and mixtures thereof And preferably a methacrylic acid copolymer or ethylcellulose can be used. However, any pharmaceutically acceptable hydrophobic polymer capable of controlling release according to the purpose of the present invention is not limited thereto.
In the present invention, the sustained release part may contain 12 to 25% by weight of the release-controlled polymer based on the total weight of the sustained release part. When the release-controlled polymer is used in an amount less than 12% by weight based on the total weight of the sustained-release polymer, it may be difficult to exhibit sustained release due to accelerated dissolution of the active ingredient. When the polymer is used in an amount exceeding 25% by weight, There is a concern.
The sustained release may further comprise a pharmaceutically acceptable excipient.
Such pharmaceutically acceptable excipients may include diluents, binders, lubricants, disintegrants, and the like. The diluent serves to increase the volume of the preparation and may be selected from one or more members selected from the group consisting of lactose, dextrin, mannitol, sorbitol, starch, microcrystalline cellulose, calcium hydrogenphosphate, anhydrous calcium hydrogenphosphate, Can be used. The binder may be dissolved in a solvent and used for increasing the binding force of the preparation. Examples of the binder include polyvinylpyrrolidone, copovidone, gelatin, starch, sucrose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose , Hydroxypropyl alkylcellulose, and mixtures thereof, may be used. The lubricant improves the fluidity of the granulate to increase the filling of the die, which is the lower part of the tablet machine, and reduces the friction between the granules and between the granules and the punch-die at the top of the tablet machine Examples of the lubricant include stearic acid, stearate, talc, corn starch, carnauba wax, light anhydrous silicic acid, magnesium silicate, synthetic aluminum silicate, hydrogenated oil, white lead, titanium oxide, microcrystalline cellulose, Macrogol 4000 and 6000, isopropyl myristate, calcium hydrogen phosphate, talc, and mixtures thereof. The disintegrant is used to absorb water and promote disintegration of the drug to improve dissolution of the drug, such as Croscamellose sodium, Sodium starch glycolate, microcrystalline cellulose, Crospovidone (cross-linked povidone) and other commercially available polyvinylpyrrolidone (PVP, Povidone), low-substituted hydroxypropyl cellulose (low substituted), alginic acid, powdered cellulose , Starch, sodium alginate, and mixtures thereof.
Preferably, the pharmaceutically acceptable excipient is selected from the group consisting of lactose, sucrose, dextrin, mannitol, sorbitol, copovidone, methylcellulose, ethylcellulose, hydroxypropylalkylcellulose, sodium croscarmellose cellulose, croscarmellose cellulose calcium, Starch, cyclodextrin, pregelatinized starch, light anhydrous silicic acid, stearic acid, magnesium stearate, sodium stearate, calcium stearate, calcium stearate, calcium stearate, sodium lauryl sulfate, sodium carboxymethylcellulose, sodium carboxymethylcellulose, sodium carboxymethylcellulose, crospovidone, carboxymethylstarch, methacrylate-divinylbenzene copolymer calcium, microcrystalline cellulose, At least one selected from the group consisting of calcium stearate, glyceryl monostearate, sodium stearyl fumarate, talc, and mixtures thereof.
In the hard capsule preparation of the present invention, the extended part may be in the form of a pellet or a mini tablet.
The pellet comprises a release coating layer comprising a) an inert core, b) a drug coating layer comprising a second drug formed on the surface of the inert core and a pharmaceutically acceptable excipient, and c) a polymer for release control formed on the surface of the drug coating layer .
As used herein, the term "inert core " refers to the core or nucleus of a drug-free pellet which is a pharmacologically active ingredient, and any conventional core material known as the inert core may be used without limitation. For example, sugar spheres, sugar, Di-tab (TM) Rhodia and spherical microcrystalline cellulose (JRS) may be used, but the present invention is not limited thereto.
In the pellet, the inert core is preferably 20 to 50% by weight based on the total weight of the pellets.
In the pellet, the drug coating layer is formed on the inert core surface in the form of a mixture of a second drug and a pharmaceutically acceptable excipient, wherein the binder is selected from the group consisting of polyvinylpyrrolidone, copovidone, gelatin, starch, sucrose , Methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylalkylcellulose, and mixtures thereof can be used. The amount of the binder to be used is not particularly limited and may be used in an amount sufficient to form a drug coating layer. The drug coating layer may further comprise a lubricant as a pharmaceutically acceptable excipient. Examples of the lubricant include stearic acid, stearic acid, talc, corn starch, carnauba wax, light anhydrous silicic acid, magnesium silicate, synthetic aluminum silicate, hydrogenated oil, white lead, titanium oxide, microcrystalline cellulose, macrogol 4000 and 6000, Calcium hydrogen phosphate, talc, and mixtures thereof.
In the pellet, the release-controlling layer formed on the surface of the drug coating layer may be one or two or more layers. Examples of the release-controlling polymer used in the release-controlling layer include a hydrophilic polymer that exhibits release control and mucoadhesiveness to improve release and sediment retention properties, or a pharmaceutical composition which is not dissolved or hardly dissolved in water together with such a hydrophilic polymer Can be used as the hydrophobic polymer. Preferably, the release-controlling layer may be formed on the surface of the drug coating layer as a single layer by mixing the hydrophilic polymer and the hydrophobic polymer. In the pellet, the release-controlling polymer may be present in an amount of 10 to 20% by weight of the hydrophilic polymer and 2 to 5% by weight of the hydrophobic polymer based on the total weight of the sustained-release part. When the content of the polymer is out of the above range, the above retention property and sustained release property may not be satisfactory.
Alternatively, the emission control layer may comprise a first emission control layer formed on the surface of the drug coating layer as a mixture of the hydrophilic polymer and the hydrophobic polymer, and a second emission control layer formed on the surface of the first emission control layer with a hydrophilic polymer have. The weight ratio of the hydrophilic polymer in the first release controlling layer and the second releasing controlling layer in the pellet may be 1 to 2: 1. If the weight ratio deviates from the above ratio, the above retention property and sustained release property may not be satisfactory.
Examples of the hydrophilic polymer include hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carbomer, polyethylene oxide, carnenan, natural gum, guar gum, tragacanth, acacia gum, locust bean gum, xanthan gum, alginate , Polyvinyl alcohol, polyvinylpyrrolidone, and mixtures thereof, and may be one selected from the group consisting of polyvinylpyrrolidone, polyvinylpyrrolidone, polyvinylpyrrolidone, and mixtures thereof. But is not limited thereto.
The release-controlling hydrophilic polymer can absorb the body fluids after oral administration to form a matrix to regulate the release of the drug, as well as to allow the slow outer layer to adhere to the gastric mucosal / mucosal layer and the continuous hydration or continuous shear action So that the adhesive can be stood on until the adhesive strength is weakened.
In one embodiment of the present invention, when high viscosity hydroxypropyl methylcellulose is used as the hydrophilic polymer for emission control, excellent release controllability and stagnation properties are achieved, preferably 50,000 to 150,000 cps, more preferably 70,000 to 12,000 cps Of high viscosity hydroxypropyl methylcellulose can be used.
In the present invention, the hydrophobic polymer which can be used as a polymer for emission control is selected from the group consisting of methacrylic acid copolymer, ethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate and mixtures thereof And preferably a methacrylic acid copolymer or ethylcellulose can be used. However, any pharmaceutically acceptable hydrophobic polymer capable of controlling release according to the purpose of the present invention is not limited thereto.
According to embodiments of the present invention, the release control layer may be formed from a mixture of high viscosity hydroxypropyl methylcellulose and ethylcellulose. The high viscosity hydroxypropylmethylcellulose may be present in an amount of 10 to 20% by weight and the ethylcellulose may be present in an amount of 2 to 5% by weight based on the total weight of the wax. If the weight ratio of hydroxypropylmethylcellulose and ethylcellulose is out of the above range, the above retention property and sustained release property may not be satisfactory.
In the present invention, by forming the release-controlling layer including the hydrophilic polymer for emission control in multiple layers, the release property and stagnation property can be further improved.
The hard capsule preparation according to the present invention may further comprise a first release controlling layer formed on the surface of the drug coating layer as a mixture of the hydrophilic polymer and the hydrophobic polymer and a second release controlling layer formed on the surface of the first release controlling layer as a hydrophilic polymer The first release control layer plays a role of regulating the release of the drug so that the drug slowly dissolves and the second release control layer not only controls the drug release but also prevents the release of the drug from the gastric mucosa / Thereby increasing the stagnation resistance.
In one embodiment of the present invention, a first release controlling layer is formed using high viscosity hydroxypropyl methylcellulose as a hydrophilic polymer for emission control and ethyl cellulose as a hydrophobic polymer, and a second release controlling layer is formed using high viscosity hydroxypropyl methylcellulose Layer exhibited excellent stagnation and sustained release properties.
According to the present invention, the extended portion in the hard capsule preparation may be a mini tablet.
In the present invention, the mini-tablet refers to a tablet made by compressing a medicine into a certain shape, but it is possible to vary the diameter of the mini-tablet differently from the ordinary tablet without change in diameter, The smaller the number, the greater the number of mini tablets that can be injected into the capsule.
Said mini tablet comprising a) an inert core, b) a drug coating layer comprising a second drug formed on the surface of the inert core and a pharmaceutically acceptable excipient, and c) a release control layer comprising a release control polymer formed on the surface of the drug coating layer, The pellet may be compression molded. In the mini tablet, the release control layer may include a first release control layer formed on the surface of the drug coating layer and including a mixture of a hydrophilic polymer and a hydrophobic polymer as a release control polymer, and a hydrophilic polymer as a release control polymer formed on the surface of the first release control layer. And the second emission control layer.
Alternatively, the mini-tablet may be a mini-tablet comprising a second drug and a pharmaceutically acceptable excipient and having a release-controlling layer comprising a release-controlling polymer on the surface thereof. In the mini-tablet, the release-controlling layer may include a first release-controlling layer formed on the surface of the mini-tablet and containing a mixture of a hydrophilic polymer and a hydrophobic polymer as a release-controlling polymer, and a hydrophilic polymer as a release-controlling polymer formed on the surface of the first release- And the second emission control layer.
Such pharmaceutically acceptable excipients may include diluents, binders, lubricants, disintegrants, and the like. The diluent serves to increase the volume of the preparation and may be selected from the group consisting of lactose, dextrin, mannitol, sorbitol, starch, microcrystalline cellulose, calcium hydrogenphosphate, anhydrous calcium hydrogenphosphate, carbonate, saccharides and mixtures thereof . The binder may be dissolved in a solvent and used for increasing the binding force of the preparation. Examples of the binder include polyvinylpyrrolidone, copovidone, gelatin, starch, sucrose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose , Hydroxypropyl alkylcellulose, and mixtures thereof, may be used. The lubricant improves the fluidity of the granulate to increase the filling of the die, which is the lower part of the tablet machine, and reduces the friction between the granules and between the granules and the punch-die at the top of the tablet machine Examples of the lubricant include stearic acid, stearate, talc, corn starch, carnauba wax, light anhydrous silicic acid, magnesium silicate, synthetic aluminum silicate, hydrogenated oil, white lead, titanium oxide, microcrystalline cellulose, Macrogol 4000 and 6000, isopropyl myristate, calcium hydrogen phosphate, talc, and mixtures thereof. The disintegrant is used to absorb water and promote disintegration of the drug to improve dissolution of the drug, such as Croscamellose sodium, Sodium starch glycolate, microcrystalline cellulose, Crospovidone (cross-linked povidone) and other commercially available polyvinylpyrrolidone (PVP, Povidone), low-substituted hydroxypropyl cellulose (low substituted), alginic acid, powdered cellulose , Starch, sodium alginate, and mixtures thereof.
The size of the mini tablet may be 2 to 6 mm in size to be inserted into the hard capsule preparation.
The hard capsule preparation according to the present invention is characterized by being able to be administered once a day.
In one embodiment according to the present invention, a release-controlled hard capsule preparation comprising a fast-release and a slow-release containing cilostazol as the same active ingredient is prepared by using 900 ml of sodium laurylsulfate (0.5%) solution as a dissolution test medium , 20 to 30% after 2 hours, 60 to 70% after 8 hours, and 90% at 24 hours after the elution test (Experimental Example 1) was carried out according to Method 2 (paddle method, 50 rpm) (Table 6). ≪ tb > < TABLE > Thus, the release-controlled hard capsule formulation of the present invention allows the rapidly released active ingredient to quickly reach the minimum effective treatment concentration, and the delayed-released active ingredient to maintain the effective blood concentration continuously for the scheduled time Not only is there an advantage, but it is also very useful in terms of pharmacology since dose and number of doses can be drastically reduced.
On the other hand, the hard capsule preparation of the present invention, in which the first drug and the second drug are different from each other, is capable of elution of time difference, so that it is more suitable for increasing the drug efficacy and decreasing side effects have.
In one embodiment of the present invention, a dissolution test was conducted on a combination preparation containing simvastatin and rosatan in the immediate-release part and the western part (Experimental example 2). As a result, the simvastatin ingredient in the immediate- (Table 9). However, it was confirmed that the dissolution of rosaceous component in the western part was delayed by 2 hours or more as compared with that of the comparative cosmetic preparation, and the preparation of the present invention showed a dissolution up to 120 minutes The dissolution rates were all within 10%, which was significantly lower than the dissolution rate (60%) of the control formulation (Table 10). Thus, the formulation of the present invention has the advantage that the time-controlled release of the two drugs can be effectively achieved, thereby reducing the side effects that can occur when the two drugs are taken at the same time.
The release-controlled hard capsule preparation according to the present invention comprises
Preparing a sustained-release formulation comprising a first drug or a pharmaceutically acceptable salt thereof and a fast acting excipient;
Preparing a sustained release comprising a second drug or a pharmaceutically acceptable salt thereof and a release controlling polymer; And
And filling the hard capsule with the inner and outer portions.
In the above production method, the step of preparing the sustained-release composition may be carried out by a method such as dry granulation, wet granulation, molten granulation, fluidized bed granule and the like. Preferably, the granules may be granulated by dry granulation, wet granulation, fluidized bed granulation, and the like.
In one embodiment of the present invention, the drug moiety is in the form of a granule and the sustained part comprises a) an inert core, b) a second drug formed on the surface of the inert core and a pharmaceutically acceptable excipient, and c) A hard capsule preparation in the form of a pellet comprising a release-controlling layer comprising a release-controlling polymer formed on a surface thereof,
Mixing and granulating a first drug or a pharmaceutically acceptable salt thereof and a rapid-acting excipient to prepare an immediate-release granule;
An inert core is coated with a coating liquid containing a second drug and a pharmaceutically acceptable excipient to form a drug coating layer,
Coating the drug coating layer with a coating solution containing a polymer for emission control to form a release controlling layer to prepare a sustained-release pellet; And
And filling the hard capsule with the sustained release granules and the sustained-release pellets.
The step of forming a release controlling layer in the manufacturing method may include forming a first release controlling layer including a mixture of a hydrophilic polymer and a hydrophobic polymer as a release controlling polymer on the surface of the drug coating layer, And forming a second emission control layer containing a hydrophilic polymer as a polymer.
In another embodiment of the present invention, when the western part is in mini-tablet form, the mini-tablet comprises a) an inert core, b) a drug coating layer comprising a second drug formed on the surface of the inert core and a pharmaceutically acceptable excipient, and c ) A pellet containing a release-controlling layer containing a release-controlling polymer formed on the surface of the drug coating layer may be compression molded. Said mini tablet comprising a) an inert core, b) a drug coating layer comprising a second drug formed on the surface of the inert core and a pharmaceutically acceptable excipient, and c) a release control layer comprising a release control polymer formed on the surface of the drug coating layer, To the pellet containing the additional pharmaceutically acceptable excipient, followed by mixing and molding. The emission control layer may be a single layer or two or more multi-layers. Wherein the emission control layer comprises a first emission control layer comprising a mixture of a hydrophilic polymer and a hydrophobic polymer as a emission control polymer on the surface of the drug coating layer and a second emission control layer comprising a hydrophilic polymer as a emission control polymer 2 release controlling layer.
Alternatively, the mini-tablet may be a mini-tablet comprising a second drug and a pharmaceutically acceptable excipient and having a release-controlling layer comprising a release-controlling polymer on the surface thereof. The mini-tablet may be prepared by granulating a mixture comprising a second drug and a pharmaceutically acceptable excipient, followed by tableting with a mini-tablet by adding an additional diluent, a binder, a disintegrant, and a lubricant, And a release controlling layer containing a release controlling polymer. The emission control layer may be a single layer or two or more multi-layers. Wherein the emission control layer comprises a first emission control layer comprising a mixture of a hydrophilic polymer and a hydrophobic polymer as a emission control polymer on the surface of the mini tablet and forming a first emission control layer on the surface of the first emission control layer comprising a hydrophilic polymer as a emission control polymer 2 release controlling layer.
Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are for further illustrating the present invention, and the scope of the present invention is not limited by these examples.
Example 1 to 3 and Comparative Example 1 and 2: Depending on the active ingredient content Internal preservation Granule and western part Pellet Preparation of a Hard Capsule Formulation Containing
According to the ingredients and contents shown in the following Table 1, cilostazol hard capsule preparations containing the immediate-release granules and the sustained-release pellets were prepared as follows.
One. Internal preservation Manufacture of granules
Cilostazol and lactose hydrate were put in a high-speed aliquot and mixed. Then, povidone K-30 solution previously dissolved in ethanol was added to prepare granules by a coalescence and granulation process. Magnesium stearate was mixed with the granules to form a fast- .
2. Western Pellet Produce
1) Formation of drug coating layer
Spherical microcrystalline cellulose having a size of 15 to 25 mesh was placed in a fluidized bed coater and coated with a coating solution prepared by dissolving cilostazol and hydroxypropylmethylcellulose as a binder in a mixed solution of water and ethanol (1: 2, weight ratio) To prepare a pellet having a coating layer formed thereon.
2) Formation of controlled release layer
The pellet formed with the drug coating layer was coated with a coating solution prepared by dissolving ethyl cellulose and hydroxypropyl methylcellulose in a mixed solution (1: 41.5, weight ratio) of water and ethanol in a fluidized bed coater to form a release controlling layer.
3. Hard capsule Filling
The prepared fast-release granules and the sustained-release pellets were filled into a No. 1 capsule using a capsule filling machine (DMF 1500, Daesan Pharmatech).
room
part
room
part
Mechanism
Mechanism
Hydroxypropylmethylcellulose
(HPMC 2208)
Example 4 to 6 and Comparative Example 3 to 5: Depending on the polymer content for emission control Internal preservation Granules and Western Pellet Preparation of a Hard Capsule Formulation Containing
According to the ingredients and contents shown in Table 2 below, cilostazol hard capsule preparations containing the immediate-preservative granules and the sustained-release pellets were prepared in the same manner as in Examples 1 to 3 and Comparative Examples 1 and 2.
room
part
room
part
Mechanism
Mechanism
Hydroxypropylmethylcellulose
(HPMC 2208)
Example 7 to 10: Internal preservation Granules and Western Pellet Preparation of a Hard Capsule Formulation Containing
The cilostazol hard capsule preparation containing the immediate-preservative granules and the sustained-release pellets was prepared according to the methods described in Examples 1 to 3 and Comparative Examples 1 and 3 according to the ingredients and contents shown in the following Table 3, 10 was prepared by coating a coating solution prepared by dissolving hydroxypropyl methylcellulose in a mixed solution of water and ethanol (1: 41.5, weight ratio) after forming a release controlling layer (first release controlling layer) on the drug coating layer, A step of forming a release controlling layer was further performed.
room
part
room
part
Mechanism
(First emission control layer)
Hydroxypropyl methylcellulose (HPMC 2208)
Mechanism
(Second emission control layer)
Hydroxypropylmethylcellulose
(HPMC 2208)
Example 11 and 12: Internal preservation Granules and Western Preparation of Hard Capsule Preparations Containing Mini Tablets
According to the ingredients and contents shown in Table 4 below, cilostazol hard capsule preparations were prepared as follows, comprising the immediate-preservative granules and the sustained-release mini-tablets as follows.
One. Internal preservation Manufacture of granules
Cilostazol and lactose hydrate were put in a high-speed aliquot and mixed. Then, povidone K-30 solution previously dissolved in ethanol was added to prepare granules by a coalescence and granulation process. Magnesium stearate was mixed with the granules to form a fast- .
2. Western Manufacture of mini tablets
1) Formation of drug coating layer
Spherical microcrystalline cellulose having a size of 15 to 25 mesh was placed in a fluidized bed coater and coated with a coating solution prepared by dissolving cilostazol and hydroxypropylmethylcellulose as a binder in a mixed solution of water and ethanol (1: 2, weight ratio) To prepare a pellet having a coating layer formed thereon.
2) Formation of controlled release layer
The pellet formed with the drug coating layer was coated with a coating solution prepared by dissolving ethyl cellulose and hydroxypropyl methylcellulose in a mixed solution (1: 41.5, weight ratio) of water and ethanol in a fluidized bed coater to form a release controlling layer. In Example 12, hydroxypropylmethylcellulose was coated with a coating solution prepared by dissolving hydroxypropylmethylcellulose in a mixed solution (1: 41.5, weight ratio) of water and ethanol after formation of the emission control layer (first emission control layer) A step of forming a release controlling layer was further performed.
3) Mini tablet tablets
Low-substituted propylcellulose as a disintegrant and magnesium stearate as a lubricant were added to the pellet having the release-controlling layer formed thereon, and the mixture was compressed with a single-handed tableting machine to prepare a mini tablet having a diameter of 4-6 mm.
3. Hard capsule Filling
The prepared fast-release granules and the western-side mini-tablets were filled into a No. 1 capsule using a capsule filling machine (DMF 1500, Daesan Pharmatech).
room
part
room
part
Mechanism
(First emission control layer)
Hydroxypropyl methylcellulose (HPMC 2208)
Mechanism
(Second emission control layer)
Hydroxypropylmethylcellulose
(HPMC 2208)
Example 13 and 14: Internal preservation Granules and Western Preparation of Hard Capsule Preparations Containing Mini Tablets
According to the ingredients and contents shown in Table 5 below, cilostazol hard capsule preparations containing the immediate-preservative granules and the sustained-release mini-tablets were prepared as follows.
One. Internal preservation Manufacture of granules
Cilostazol and lactose hydrate were put in a high-speed aliquot and mixed. Then, povidone K-30 solution previously dissolved in ethanol was added to prepare granules by a coalescence and granulation process. Magnesium stearate was mixed with the granules to form a fast- .
2. Western Manufacture of mini tablets
1) Tablets in the western part of the mini tablet
After mixing cilostazol with microcrystalline cellulose, hydroxypropylmethyl cellulose, high viscosity hydroxypropyl methylcellulose (100,000 cps, HPMC 2208) and low-substituted hydroxypropyl cellulose (LHPC), povidone K-30 The resulting solution was combined and granulated. After drying and sizing, magnesium stearate was added and mixed, and the tablets were tableted with a single tablet machine.
2) Formation of controlled release layer of the western part mini tablet
The mini tablet was placed in a pan coater and coated with a coating solution prepared by dissolving ethyl cellulose and hydroxypropyl methylcellulose in a mixed solution of water and ethanol (1: 41.5, weight ratio) to form a release controlling layer. In the case of Example 14, hydroxypropylmethylcellulose was coated with a coating solution prepared by dissolving hydroxypropylmethylcellulose in a mixed solution (1: 41.5, weight ratio) of water and ethanol after formation of the emission control layer (first emission control layer) A step of forming a release controlling layer was further performed.
3. Hard capsule Filling
The prepared fast-release granules and the western-side mini-tablets were filled into a No. 1 capsule using a capsule filling machine (DMF 1500, Daesan Pharmatech).
room
part
room
part
Mechanism
(First emission control layer)
Hydroxypropyl methylcellulose (HPMC 2208)
Mechanism
(Second emission control layer)
Hydroxypropylmethylcellulose
(HPMC 2208)
Experimental Example One: Cilostazol Dissolution test of preparation
Dissolution tests were conducted to evaluate the dissolution rates of the cilostazol preparations of Examples 1 to 14 and Comparative Examples 1 to 5.
The dissolution test was carried out by using 900 ml of sodium lauryl sulfate (0.5%) as a dissolution test medium, 50 rotations per minute according to Korean Pharmacopoeia dissolution assay method (paddle method), and a dissolution temperature of 37 ± 0.5 ° C . 5 ml of the eluate was collected from each of the vessels at 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours after initiation of the elution test and filtered through a 0.45 탆 membrane filter. Was used as the sample solution, and the absorbances At and As were measured at a wavelength of 257 nm using a UV (spectrophotometer, Shimadzu, Japan). The results of the dissolution test are shown in Table 6.
The release-controlled hard capsule preparation according to the present invention was prepared by dissolving 900 ml of sodium lauryl sulfate (0.5%) in a dissolution test medium and performing a dissolution test according to Korean Pharmacopoeia dissolution assay method 2 (paddle method, 50 rpm) , 20-30% after 2 hours, 60-70% after 8 hours and 90% or more at 24 hours. In Comparative Example 1, the initial dissolution rate was too low, the active ingredient eluted slowly, and in Comparative Example 2, excessive drug eluted in the early stage, but the overall dissolution rate was low. In Comparative Examples 3, 4 and 5, the late dissolution rate was low and did not satisfy the dissolution criterion.
Example 15 and 16: Internal preservation Granules and Western Pellet Preparation of a Hard Capsule Agent (Composite) Containing
In the same manner as in Examples 1 to 3 and Comparative Examples 1 and 2, according to the ingredients and the contents described in the following Table 7, except that the sustained-release drug was used as simvastatin and the sustained- A hard capsule preparation containing granules and sustained-release pellets was prepared. In Example 16, hydroxypropylmethylcellulose was dissolved in a mixed solution (1: 41.5, weight ratio) of hydroxypropylmethylcellulose after forming a release controlling layer (first release controlling layer) on the drug coating layer Thereby forming a second emission control layer.
room
part
room
part
Mechanism
(First emission control layer)
Hydroxypropylmethylcellulose
(HPMC 2208)
Mechanism
(Second emission control layer)
Hydroxypropylmethylcellulose
(HPMC 2208)
Example 17: Internal preservation Granules and Western Preparation of Hard Capsule Formulation (Composite) Containing Mini Tablets
In accordance with the components and contents shown in Table 8 below, except that the sustained-release drug was used as simvastatin and the sustained-release drug was used as rosavast, the sustained-release granules and the sustained-release mini-tablets were contained in the same manner as in Example 11 Lt; RTI ID = 0.0 > capsule. ≪ / RTI > However, in the case of Example 18, hydroxypropyl methylcellulose was prepared by dissolving hydroxypropylmethylcellulose in a mixed solution (1: 41.5, weight ratio) of water and ethanol after formation of a release controlling layer (first release controlling layer) Coating with a coating liquid to form a second emission control layer.
room
part
room
part
Mechanism
(First emission control layer)
Hydroxypropylmethylcellulose
(HPMC 2208)
Mechanism
(Second emission control layer)
Hydroxypropylmethylcellulose
(HPMC 2208)
Experimental Example 2: Combination Dissolution test
In order to evaluate the dissolution rates of the combination preparations of Examples 15 to 18, a dissolution test was carried out.
The dissolution test method for each component was as follows. Simvastatin single agent (Zocor®, Korean MSD) and Rosatane single agent (Kozan®, Korea MSD) were used as control agents, and the results are shown in Tables 9 and 10 .
[Simvastatin dissolution test]
Dissolution test basis: Dissolution test method of Korean Pharmacopoeia
Test method: paddle method, 50 revolutions per minute
Test solution:
1) 0.01 M hydrochloric acid solution, 750 mL (0-2 hours)
2) pH 6.8 artificial intestinal fluid, 1,000 mL (after 2 hours)
Analytical method: Extracellular absorption spectrophotometry (detection wavelength up to 244 nm)
[How to test Rosa Tan]
Dissolution test basis: Dissolution test method of Korean Pharmacopoeia
Test method: paddle method, 50 revolutions per minute
Test solution:
1) 0.01 M hydrochloric acid solution, 750 mL (0-2 hours)
2) pH 6.8 artificial intestinal fluid, 1,000 mL (after 2 hours)
Analytical method: Extracellular absorption spectrophotometry (detection wavelength up to 240 nm)
The simvastatin ingredient of the immediate-preservative was found to exhibit almost the same dissolution characteristics as compared with the control drug, Zocor® (Table 9), but the dissolution of rosatan in the western part was delayed by more than 2 hours (Table 10). In the formulation of the present invention, the dissolution rate of the losartan component was all within 10% until 120 minutes, which was significantly lower than the dissolution rate (60%) of the control preparation. Thus, it can be seen that the formulation of the present invention effectively achieves time-controlled release of the two drugs.
Claims (19)
(2) A hard capsule preparation comprising a sustained release comprising a second drug or a pharmaceutically acceptable salt thereof and a release-controlling polymer,
Wherein the sustained release is in the form of pellets or mini-tablets wherein the pellets are compression molded, the pellets comprising (a) an inert core, (b) a second drug formed on the surface of the inert core or a pharmaceutically acceptable salt thereof, And (c) a release controlling layer formed on the surface of the drug coating layer, wherein the release controlling layer is a release controlling polymer formed on the surface of the drug coating layer, wherein the hydrophilic polymer and the hydrophobic polymer And a second release controlling layer comprising a hydrophilic polymer having a mucoadhesive property as a release controlling polymer formed on the surface of the first release controlling layer, wherein the second release controlling layer comprises a mixture of the first release controlling layer and the second release controlling layer,
Wherein the first drug and the second drug are both cilostazol or a pharmaceutically acceptable salt thereof or the first drug is simvastatin or a pharmaceutically acceptable salt thereof and the second drug is rosatan or a pharmaceutical Lt; RTI ID = 0.0 >
The hydrophilic polymer contained in the first release control layer may be at least one selected from the group consisting of hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carbomer, polyethylene oxide, carnenan, natural gum, guar gum, tragacanth, Wherein the hydrophilic polymer is at least one hydrophilic polymer selected from the group consisting of silica gel, locust gum, xanthan gum, alginate, polyvinyl alcohol, polyvinyl pyrrolidone, and mixtures thereof,
The hydrophobic polymer contained in the first release controlling layer may be at least one selected from the group consisting of methacrylic acid copolymer, ethyl cellulose, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, cellulose acetate phthalate, Or more,
Wherein the hydrophilic polymer having mucoadhesive properties is hydroxypropylmethylcellulose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150165457A KR101869406B1 (en) | 2015-11-25 | 2015-11-25 | Controlled Released Hard Capsule Preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150165457A KR101869406B1 (en) | 2015-11-25 | 2015-11-25 | Controlled Released Hard Capsule Preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170061219A KR20170061219A (en) | 2017-06-05 |
| KR101869406B1 true KR101869406B1 (en) | 2018-07-24 |
Family
ID=59222956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150165457A KR101869406B1 (en) | 2015-11-25 | 2015-11-25 | Controlled Released Hard Capsule Preparation |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101869406B1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102034694B1 (en) | 2017-12-14 | 2019-10-22 | 한국유나이티드제약 주식회사 | Cored tablet comprising mosapride and rabeprazole |
| KR102145853B1 (en) * | 2018-06-19 | 2020-08-19 | 한국유나이티드제약 주식회사 | Pharma ceutical Composition Comprising Cilostazol and Statin derivatives |
| KR20200077911A (en) * | 2018-12-21 | 2020-07-01 | (주)유케이케미팜 | A pharmaceutical composition of sustained-release comprising zaltoprofen |
| KR102612984B1 (en) * | 2019-04-02 | 2023-12-13 | 한미약품 주식회사 | Pharmaceutical composition comprising esomeprazole, or pharmaceutically acceptable salt thereof with dual release profile |
| CN115607539A (en) * | 2022-10-17 | 2023-01-17 | 广东省第二人民医院（广东省卫生应急医院） | Polyphenol compound medicine and slow release method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030077297A1 (en) * | 1999-02-26 | 2003-04-24 | Feng-Jing Chen | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US20080085306A1 (en) * | 2006-08-31 | 2008-04-10 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090297596A1 (en) * | 2005-05-23 | 2009-12-03 | Elan Pharma International Limited | Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor |
| KR100762847B1 (en) * | 2006-01-27 | 2007-10-04 | 씨제이 주식회사 | Multiple unit type sustained release oral formulation and process for the preparation thereof |
-
2015
- 2015-11-25 KR KR1020150165457A patent/KR101869406B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030077297A1 (en) * | 1999-02-26 | 2003-04-24 | Feng-Jing Chen | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US20080085306A1 (en) * | 2006-08-31 | 2008-04-10 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170061219A (en) | 2017-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101190708B1 (en) | Sustained-release pharmaceutical composition comprising mosapride or salt thereof | |
| KR101869406B1 (en) | Controlled Released Hard Capsule Preparation | |
| JP6976946B2 (en) | A pharmaceutical composition containing an inhibitor of URAT1 having strong bioactivity. | |
| KR101094231B1 (en) | Sustained release solid formulations and methods of manufacturing the same | |
| KR101207618B1 (en) | Pharmaceutical formulation for treating cardiovascular disease | |
| EP2275093A2 (en) | Pharmaceutical formulation | |
| KR101205633B1 (en) | Pharmaceutical formulation for treating cardiovascular disease | |
| EP2373319B1 (en) | Sustained release pharmaceutical composition of quetiapine and process for preparation thereof | |
| US20100092554A1 (en) | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof | |
| JP2023026623A (en) | Pharmaceutical formulation with excellent dissolution property containing esomeprazole and sodium bicarbonate | |
| KR101269829B1 (en) | Sustained release preparation using gastric retentive drug delivery system | |
| KR20120094882A (en) | Sustained-release pharmaceutical composition comprising mosapride or salt thereof | |
| TW201206501A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| EP2533767A1 (en) | Pharmaceutical compositions comprising a combination of metformin and sitagliptin | |
| WO2010026467A2 (en) | Controlled release dosage form of high solubility active ingredient | |
| TWI608849B (en) | High drug load pharmaceutical compositions with controllable release rate and production methods thereof | |
| KR101002583B1 (en) | Methods of manufacturing sustained release solid formulations | |
| KR101265491B1 (en) | Dissolution rate controlled multilayered tablet for oral administration containing sarpogrelate hydrochloride and manufacturing method thereof | |
| KR20170001545A (en) | Mosapride sustained-release formulation and Composite formulation comprising mosapride and rabeprazole | |
| US8512746B2 (en) | Extended release pharmaceutical compositions of levetiracetam | |
| KR20090047310A (en) | Multilayered tablet containing dexibuprofen | |
| KR20090107960A (en) | Pharmaceutical formulation for treating cardiovascular disease | |
| KR20190092805A (en) | Pharmaceutical composition comprising Acetylsalicylic acid and Lansoprazole | |
| KR20160120503A (en) | Chrono-system formulation for Celecoxib | |
| WO2015063670A1 (en) | Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) |